Equities Analysts Offer Predictions for APGE Q1 Earnings

Apogee Therapeutics, Inc. (NASDAQ:APGE - Free Report) - Investment analysts at Wedbush issued their Q1 2026 earnings estimates for shares of Apogee Therapeutics in a research report issued to clients and investors on Monday, May 12th. Wedbush analyst D. Nierengarten expects that the company will post earnings of ($0.98) per share for the quarter. Wedbush currently has a "Outperform" rating and a $90.00 target price on the stock. The consensus estimate for Apogee Therapeutics' current full-year earnings is ($3.09) per share. Wedbush also issued estimates for Apogee Therapeutics' Q2 2026 earnings at ($1.01) EPS, Q3 2026 earnings at ($1.03) EPS and Q4 2026 earnings at ($1.06) EPS.

Apogee Therapeutics (NASDAQ:APGE - Get Free Report) last released its quarterly earnings results on Monday, May 12th. The company reported ($0.95) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.19) by $0.24.

Several other equities research analysts have also issued reports on APGE. Citigroup started coverage on shares of Apogee Therapeutics in a research note on Thursday, March 13th. They issued a "buy" rating and a $95.00 price objective for the company. Guggenheim restated a "buy" rating on shares of Apogee Therapeutics in a report on Monday, February 10th. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has an average rating of "Buy" and an average price target of $94.60.

Apogee Therapeutics Price Performance

Shares of Apogee Therapeutics stock opened at $39.58 on Tuesday. The business's fifty day moving average price is $36.43 and its two-hundred day moving average price is $41.42. The company has a market capitalization of $1.78 billion, a P/E ratio of -16.36 and a beta of 1.70. Apogee Therapeutics has a 1-year low of $26.20 and a 1-year high of $63.50.

Hedge Funds Weigh In On Apogee Therapeutics

Several large investors have recently made changes to their positions in the stock. GF Fund Management CO. LTD. purchased a new stake in Apogee Therapeutics during the 4th quarter valued at approximately $43,000. GAMMA Investing LLC boosted its holdings in Apogee Therapeutics by 3,560.1% in the 1st quarter. GAMMA Investing LLC now owns 5,417 shares of the company's stock worth $202,000 after acquiring an additional 5,269 shares during the period. Optimize Financial Inc purchased a new position in Apogee Therapeutics in the fourth quarter valued at about $203,000. Aigen Investment Management LP acquired a new position in shares of Apogee Therapeutics in the 4th quarter worth approximately $216,000. Finally, BNP Paribas Financial Markets bought a new stake in shares of Apogee Therapeutics in the 4th quarter worth approximately $219,000. 79.04% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Apogee Therapeutics

In related news, insider Carl Dambkowski sold 1,590 shares of the firm's stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $30.48, for a total transaction of $48,463.20. Following the sale, the insider now owns 251,033 shares in the company, valued at approximately $7,651,485.84. This trade represents a 0.63% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Michael Thomas Henderson sold 10,000 shares of Apogee Therapeutics stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $30.15, for a total transaction of $301,500.00. Following the sale, the chief executive officer now directly owns 1,292,987 shares in the company, valued at approximately $38,983,558.05. This trade represents a 0.77% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 18,175 shares of company stock valued at $587,191. 36.10% of the stock is currently owned by company insiders.

Apogee Therapeutics Company Profile

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.